Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam ATTR Drug Receives Orphan Drug Status in Europe

Premium

Alnylam Pharmaceuticals this week announced that its transthyretin-mediated amyloidosis drug ALN-TTRsc has received orphan drug status from European regulators.

ALN-TTRsc is a subcutaneously administered version of the company's ATTR drug patisiran, an intravenous therapy currently in Phase III testing in patients with a manifestation of the disease called familial amyloidotic polyneuropathy.

The subcutaneous version recently entered Phase II testing for a version of ATTR called cardiac amyloidosis. That trial is assessing the tolerability of the drug, as well as its effect on knocking down serum levels of its target protein, in 15 patients. Data from the trial is expected later this year.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.